| Literature DB >> 35012679 |
Cédric Hirzel1, Alexia Cusini2, Katarzyna Szajek3, Felix Fleisch4, Sandra Hutter5, Martin Risch5, Theresa Bechmann6, Valerie A Luyckx7, Sabine Güsewell8, Amico Study Group.
Abstract
BACKGROUND: Health care workers (HCW) are heavily exposed to SARS-CoV-2 from the beginning of the pandemic. We aimed to analyze risk factors for SARS-CoV-2 seroconversion among HCW with a special emphasis on the respective healthcare institutions' recommendation regarding the use of FFP-2 masks.Entities:
Keywords: FFP-2 and surgical masks; Healthcare workers; Mask policy; SARS-CoV-2; Seroconversion
Mesh:
Substances:
Year: 2022 PMID: 35012679 PMCID: PMC8744038 DOI: 10.1186/s13756-021-01047-x
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fig. 1Timeline of the study. The pandemic in the Canton of Grisons from March 2020 to March 2021 is represented by the 7-day running mean of daily numbers of new COVID-19 cases. Horizontal bars indicate the time of baseline and follow up sampling in the participating health care institutions (HCIs)
Fig. 2Flow diagram for study participants
Characteristics of study participants according to the mask policy of the respective health care institution
| FFP-2 masks recommended exclusively for aerosol generating procedures in patients with COVID-19 | FFP-2 masks recommended for all interactions with patients with COVID-19 | |
|---|---|---|
| Number of health care institutions | 7 | 6 |
| Number of participants (n = 2794) | 1993 | 801 |
| Age, median (IQR) | 42 (31–52) | 45 (33–54) |
| Sex: n (%) female | 1579 (79.2%) | 618 (77.2%) |
| Profession | ||
| Employee without patient exposure | 406 (20.4%) | 153 (19.1%) |
| Nurse | 823 (41.3%) | 295 (36.8%) |
| Physician | 305 (15.3%) | 71 (8.9%) |
| Other employee with patient exposure | 459 (23.0%) | 282 (35.2%) |
| Employee in ICU | 168 (8.4%) | 19 (2.4%) |
| Employee in COVID-19 ward | 186 (9.3%) | 60 (7.5%) |
| Employee in emergency unit | 309 (15.5%) | 87 (10.9%) |
| Type of patient exposure | ||
| No patient exposure | 601 (30.2%) | 244 (30.5%) |
| Exposure to non-COVID-19 patients | 827 (41.5%) | 384 (47.9%) |
| Exposure to COVID-19 patients | 532 (26.7%) | 169 (21.1%) |
| Exposure to SARS-CoV2 infected co-worker | 297 (14.9%) | 86 (10.7%) |
| Non-occupational exposure to SARS-CoV2 infected person | 58 (2.9%) | 33 (4.1%) |
| Type of patient exposure | ||
| No patient exposure | 499 (30.5%) | 210 (35.5%) |
| Exposure to non-COVID-19 patients | 339 (20.7%) | 154 (26.1%) |
| Exposure to COVID-19 patients | 729 (44.6%) | 208 (35.2%) |
| Exposure to SARS-CoV2 infected co-worker | 322 (19.7%) | 123 (20.8%) |
| Non-occupational exposure to SARS-CoV2 infected person | 161 (9.8%) | 70 (11.8%) |
| Cumulative regional incidence per 100,000 inhabitants (July 2020/March 2021), mean | 340/5298 | 539/6432 |
Risk factors for SARS-CoV-2 seroconversion
| Baseline n = 2794 | Follow up n = 2227 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n total | n sero-conversion | % sero-conversion | OR | 95% CI | n total | N sero-conversion | % Sero-conversion | OR | 95% CI | |||
| Per 10 years | 2794 | 99 | 1.10 | 0.93–1.29 | 0.267 | 2227 | 290 | 0.99 | 0.98–1.00 | 0.104 | ||
| Female | 2197 | 76 | 3.5 | 1763 | 227 | 12.9 | ||||||
| Male | 597 | 23 | 3.9 | 1.12 | 0.68–1.77 | 0.645 | 464 | 63 | 13.6 | 1.06 | 0.78–1.43 | 0.689 |
| 0 | 722 | 25 | 3.5 | 695 | 74 | 10.6 | ||||||
| A | 693 | 32 | 4.6 | 1.35 | 0.79–2.32 | 0.271 | 654 | 107 | 16.4 | 1.64 | 1.20–2.26 | 0.002 |
| B | 182 | 7 | 3.8 | 1.12 | 0.44–2.49 | 0.802 | 173 | 23 | 13.3 | 1.29 | 0.77–2.09 | 0.324 |
| AB | 64 | 0 | 0.0 | 0.00 | 0.00–15.72 | 0.977 | 64 | 14 | 21.9 | 2.35 | 1.20–4.35 | 0.009 |
| unknown | 1133 | 35 | 3.1 | 0.89 | 0.53–1.51 | 0.658 | 641 | 72 | 11.2 | 1.06 | 0.75–1.50 | 0.732 |
| < 60% | 514 | 15 | 2.9 | 410 | 61 | 14.9 | ||||||
| 60–79% | 359 | 14 | 3.9 | 1.35 | 0.64–2.85 | 0.427 | 293 | 38 | 13.0 | 0.85 | 0.55–1.31 | 0.473 |
| 80–100% | 1873 | 69 | 3.7 | 1.27 | 0.74–2.33 | 0.405 | 1436 | 182 | 12.7 | 0.83 | 0.61–1.14 | 0.245 |
| Employee without patient exposure | 559 | 11 | 2.0 | 478 | 48 | 10.0 | ||||||
| Physician | 376 | 9 | 2.4 | 1.22 | 0.49–2.98 | 0.660 | 273 | 28 | 10.3 | 1.02 | 0.62–1.66 | 0.925 |
| Nurse | 1118 | 51 | 4.6 | 2.38 | 1.28–4.85 | 0.010 | 886 | 143 | 16.1 | 1.72 | 1.23–2.46 | 0.002 |
| Other employee with patient exposure | 741 | 28 | 3.8 | 1.96 | 0.99–4.14 | 0.063 | 590 | 71 | 12.0 | 1.23 | 0.83–1.81 | 0.304 |
| None | 845 | 18 | 2.1 | 709 | 74 | 10.4 | ||||||
| No COVID-19 patients | 1211 | 34 | 2.8 | 1.33 | 0.75–2.41 | 0.337 | 493 | 50 | 10.1 | 0.97 | 0.66–1.41 | 0.869 |
| With COVID-19 patients | 701 | 46 | 6.6 | 3.23 | 1.89–5.76 | < 0.001 | 937 | 157 | 16.8 | 1.73 | 1.29–2.33 | < 0.001 |
| No | 664 | 42 | 6.3 | 880 | 149 | 16.9 | ||||||
| Yes | 38 | 4 | 10.5 | 1.74 | 0.50–4.63 | 0.315 | 58 | 9 | 15.5 | 0.90 | 0.40–1.79 | 0.780 |
| No | 1675 | 67 | 4.0 | 1219 | 177 | 14.5 | ||||||
| Yes | 253 | 14 | 5.5 | 1.41 | 0.75–2.47 | 0.259 | 213 | 30 | 14.1 | 0.97 | 0.63–1.45 | 0.868 |
| No | 1681 | 52 | 3.1 | 1151 | 148 | 12.9 | ||||||
| Yes | 246 | 29 | 11.8 | 4.19 | 2.57–6.69 | < 0.001 | 281 | 59 | 21.0 | 1.80 | 1.28–2.51 | 0.001 |
| No | 1531 | 57 | 3.7 | 1114 | 166 | 14.9 | ||||||
| Yes | 396 | 24 | 6.1 | 1.67 | 1.00–2.69 | 0.041 | 318 | 41 | 12.9 | 0.85 | 0.58–1.21 | 0.37 |
| No | 2368 | 58 | 2.4 | 1665 | 200 | 12.0 | ||||||
| Yes | 383 | 40 | 10.4 | 4.64 | 3.04–7.04 | < 0.001 | 445 | 73 | 16.4 | 1.44 | 1.07–1.92 | 0.015 |
| No or unknown | 2660 | 83 | 3.1 | 1810 | 166 | 9.2 | ||||||
| Household | 30 | 12 | 40.0 | 20.70 | 9.43–43.99 | < 0.001 | 172 | 82 | 47.7 | 9.02 | 6.43–12.67 | < 0.001 |
| Outside household | 61 | 3 | 4.9 | 1.61 | 0.39–4.46 | 0.432 | 157 | 33 | 21.0 | 2.64 | 1.72–3.95 | < 0.001 |
| No | 2081 | 73 | 3.5 | 1635 | 209 | 12.8 | ||||||
| Yes | 669 | 25 | 3.7 | 1.07 | 0.66–1.67 | 0.781 | 504 | 72 | 14.3 | 1.14 | 0.85–1.51 | 0.383 |
| Low | 2393 | 79 | 3.3 | 1879 | 219 | 11.7 | ||||||
| Medium | 141 | 1 | 0.7 | 0.16 | 0.01–1.94 | 0.151 | 129 | 23 | 17.8 | 1.68 | 0.78–3.61 | 0.184 |
| High | 260 | 19 | 7.3 | 1.88 | 0.50–7.12 | 0.353 | 219 | 48 | 21.9 | 2.06 | 1.10–3.89 | 0.025 |
| Specific use | 1993 | 68 | 3.4 | 1636 | 204 | 12.5 | ||||||
| General use | 801 | 31 | 3.9 | 0.70 | 0.20–2.40 | 0.567 | 591 | 86 | 14.6 | 1.14 | 0.60–2.16 | 0.693 |
Participants who seroconverted before the baseline assessment (n = 99) were excluded for analysis of seroconversion at follow-up. Note that total n for individual risk factors may be smaller due to missing values
*For these factors determined at institutional level regression models included health care institutions as random effect
Fig. 3Risk factors associated with SARS-CoV-2 seroconversion (multivariate model) at baseline. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) as well as p values (Wald tests) derived from a logistic mixed-effects model for seroconversion at baseline (n = 2749)
Fig. 4Risk factors associated with SARS-CoV-2 seroconversion (multivariate model) at follow-up. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) as well as p values (Wald tests) derived from a logistic mixed-effects model for seroconversion at survey 2 (n = 2139)